Anileridine
Systematic (IUPAC) name | |
---|---|
Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
|
|
Clinical data | |
AHFS/Drugs.com | monograph |
Legal status |
|
Routes of administration |
Tablets, injection |
Pharmacokinetic data | |
Protein binding | > 95% |
Metabolism | Hepatic |
Identifiers | |
CAS Number | 144-14-9 |
ATC code | N01AH05 (WHO) |
PubChem | CID: 8944 |
IUPHAR/BPS | 7115 |
DrugBank | DB00913 |
ChemSpider | 8600 |
UNII | 71Q1A3O279 |
KEGG | D02941 |
ChEBI | CHEBI:61203 |
ChEMBL | CHEMBL1201347 |
Chemical data | |
Formula | C22H28N2O2 |
Molecular mass | 352.47 g/mol |
|
|
|
|
Physical data | |
Melting point | 83 °C (181 °F) |
(what is this?) (verify) |
Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s.[1] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.
Anileridine is no longer manufactured in the US or Canada.[2] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate [3] It is also under international control per UN treaties.
Administration
Pharmacokinetics
Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[5] It is mostly metabolized by the liver.
References
- ↑ U.S. Patent 2,897,204
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ http://www.deadiversion.usdoj.gov/fed_regs/quotas/2014/fr0825.htm
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>